Home > > Europe And Global Vaccines Market- Size, Share, Growth Rate, and Forecast
TABLE OF CONTENTS CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: EUROPE VACCINES MARKET 3.1. OVERVIEW 3.2. EUROPE 3.2.1. EUROPE VACCINES MARKET, BY TECHNOLOGY 3.2.2. EUROPE VACCINES MARKET, BY TYPE 3.2.3. EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4. EUROPE VACCINES MARKET, BY COUNTRY 3.2.4.1. GERMANY 3.2.4.1.1. GERMANY VACCINES MARKET, BY TECHNOLOGY 3.2.4.1.2. GERMANY VACCINES MARKET, BY TYPE 3.2.4.1.3. GERMANY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.2. UK 3.2.4.2.1. UK VACCINES MARKET, BY TECHNOLOGY 3.2.4.2.2. UK VACCINES MARKET, BY TYPE 3.2.4.2.3. UK VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.3. FRANCE 3.2.4.3.1. FRANCE VACCINES MARKET, BY TECHNOLOGY 3.2.4.3.2. FRANCE VACCINES MARKET, BY TYPE 3.2.4.3.3. FRANCE VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.4. ITALY 3.2.4.4.1. ITALY VACCINES MARKET, BY TECHNOLOGY 3.2.4.4.2. ITALY VACCINES MARKET, BY TYPE 3.2.4.4.3. ITALY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.5. SPAIN 3.2.4.5.1. SPAIN VACCINES MARKET, BY TECHNOLOGY 3.2.4.5.2. SPAIN VACCINES MARKET, BY TYPE 3.2.4.5.3. SPAIN VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.6. ROE 3.2.4.6.1. ROE VACCINES MARKET, BY TECHNOLOGY 3.2.4.6.2. ROE VACCINES MARKET, BY TYPE 3.2.4.6.3. ROE VACCINES MARKET, BY ROUTE OF ADMINISTRATION CHAPTER 4: GLOBAL VACCINES MARKET, BY TECHNOLOGY 4.1. OVERVIEW 4.2. CONJUGATE VACCINES 4.2.1. CONJUGATE VACCINES MARKET, BY REGION 4.2.1.1. NORTH AMERICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.2. EUROPE CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.3. ASIA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.3. INACTIVATED AND SUBUNIT VACCINES 4.3.1. INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION 4.3.1.1. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.2. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.3. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.4. LIVE ATTENUATED VACCINES 4.4.1. LIVE ATTENUATED VACCINES MARKET, BY REGION 4.4.1.1. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.2. EUROPE LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.3. ASIA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.4. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.5. RECOMBINANT VACCINES 4.5.1. RECOMBINANT VACCINES MARKET, BY REGION 4.5.1.1. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.2. EUROPE RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.3. ASIA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.4. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.6. TOXOID VACCINES 4.6.1. TOXOID VACCINES MARKET, BY REGION 4.6.1.1. NORTH AMERICA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.2. EUROPE TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.3. ASIA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.4. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET, BY COUNTRY CHAPTER 5: GLOBAL VACCINES MARKET, BY TYPE 5.1. OVERVIEW 5.2. MONOVALENT VACCINES 5.2.1. MONOVALENT VACCINES MARKET, BY REGION 5.2.1.1. NORTH AMERICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.2. EUROPE MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.3. ASIA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.3. MULTIVALENT VACCINES 5.3.1. MULTIVALENT VACCINES MARKET, BY REGION 5.3.1.1. NORTH AMERICA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.2. EUROPE MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.3. ASIA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET, BY COUNTRY CHAPTER 6: GLOBAL VACCINES MARKET, BY ROUTE OF ADMINISTRATION 6.1. OVERVIEW 6.2. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 6.2.1. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY REGION 6.2.1.1. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.2. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.3. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.3. ORAL ADMINISTRATION 6.3.1. ORAL ADMINISTRATION MARKET, BY REGION 6.3.1.1. NORTH AMERICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.2. EUROPE ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.3. ASIA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.4. OTHER ROUTES OF ADMINISTRATION 6.4.1. OTHER ROUTES OF ADMINISTRATION MARKET, BY REGION 6.4.1.1. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.2. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.3. ASIA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.4. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY TABLE 81. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF TABLES TABLE 01. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 02. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 03. TABLE 04. SOURCE: PRIMARY RESEARCH, GOVERNMENT PUBLICATIONS, COMPANY RELEASES, AND 1000IQMR ANALYSISGLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 05. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 07. EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($MILLION) TABLE 08. EUROPE VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($MILLION) TABLE 09. EUROPE VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($MILLION) TABLE 10. EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 11. GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 12. GERMANY VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 13. GERMANY VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 14. UK VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 15. UK VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 16. UK VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 17. FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 18. FRANCE VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 19. FRANCE VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 20. ITALY VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 21. ITALY VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 22. ITALY VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 23. SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 24. SPAIN VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 25. SPAIN VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 26. ROE VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 27. ROE VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 28. ROE VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 29. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 30. CONJUGATE VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 31. NORTH AMERICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. EUROPE CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. ASIA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 36. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. LIVE ATTENUATED VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 41. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. EUROPE LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. ASIA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. RECOMBINANT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 46. NORTH AMERICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. EUROPE RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. ASIA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. TOXOID VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 51. NORTH AMERICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. EUROPE TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. ASIA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 56. MONOVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 57. NORTH AMERICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. EUROPE MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. ASIA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 61. MULTIVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 62. NORTH AMERICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. EUROPE MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. ASIA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. GLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 67. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 68. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 72. ORAL ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 73. NORTH AMERICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. EUROPE ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. ASIA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 76. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 77. OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 78. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 79. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 80. ASIA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 81. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)LIST OF FIGURES CHAPTER 1: RESEARCH METHODOLOGY 1.1. Delivery Model 1.2. Hypothesis Creation 1.3. Revenue narrow down of Companies and in-depth interviews 1.4. Data Triangulation and Validation 1.5. About Us 1.6. Key market segments CHAPTER 2: PREMIUM INSIGHTS CHAPTER 3: EUROPE VACCINES MARKET 3.1. OVERVIEW 3.2. EUROPE 3.2.1. EUROPE VACCINES MARKET, BY TECHNOLOGY 3.2.2. EUROPE VACCINES MARKET, BY TYPE 3.2.3. EUROPE VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4. EUROPE VACCINES MARKET, BY COUNTRY 3.2.4.1. GERMANY 3.2.4.1.1. GERMANY VACCINES MARKET, BY TECHNOLOGY 3.2.4.1.2. GERMANY VACCINES MARKET, BY TYPE 3.2.4.1.3. GERMANY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.2. UK 3.2.4.2.1. UK VACCINES MARKET, BY TECHNOLOGY 3.2.4.2.2. UK VACCINES MARKET, BY TYPE 3.2.4.2.3. UK VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.3. FRANCE 3.2.4.3.1. FRANCE VACCINES MARKET, BY TECHNOLOGY 3.2.4.3.2. FRANCE VACCINES MARKET, BY TYPE 3.2.4.3.3. FRANCE VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.4. ITALY 3.2.4.4.1. ITALY VACCINES MARKET, BY TECHNOLOGY 3.2.4.4.2. ITALY VACCINES MARKET, BY TYPE 3.2.4.4.3. ITALY VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.5. SPAIN 3.2.4.5.1. SPAIN VACCINES MARKET, BY TECHNOLOGY 3.2.4.5.2. SPAIN VACCINES MARKET, BY TYPE 3.2.4.5.3. SPAIN VACCINES MARKET, BY ROUTE OF ADMINISTRATION 3.2.4.6. ROE 3.2.4.6.1. ROE VACCINES MARKET, BY TECHNOLOGY 3.2.4.6.2. ROE VACCINES MARKET, BY TYPE 3.2.4.6.3. ROE VACCINES MARKET, BY ROUTE OF ADMINISTRATION CHAPTER 4: GLOBAL VACCINES MARKET, BY TECHNOLOGY 4.1. OVERVIEW 4.2. CONJUGATE VACCINES 4.2.1. CONJUGATE VACCINES MARKET, BY REGION 4.2.1.1. NORTH AMERICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.2. EUROPE CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.3. ASIA CONJUGATE VACCINES MARKET, BY COUNTRY 4.2.1.4. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET, BY COUNTRY 4.3. INACTIVATED AND SUBUNIT VACCINES 4.3.1. INACTIVATED AND SUBUNIT VACCINES MARKET, BY REGION 4.3.1.1. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.2. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.3. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.3.1.4. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET, BY COUNTRY 4.4. LIVE ATTENUATED VACCINES 4.4.1. LIVE ATTENUATED VACCINES MARKET, BY REGION 4.4.1.1. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.2. EUROPE LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.3. ASIA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.4.1.4. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET, BY COUNTRY 4.5. RECOMBINANT VACCINES 4.5.1. RECOMBINANT VACCINES MARKET, BY REGION 4.5.1.1. NORTH AMERICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.2. EUROPE RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.3. ASIA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.5.1.4. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET, BY COUNTRY 4.6. TOXOID VACCINES 4.6.1. TOXOID VACCINES MARKET, BY REGION 4.6.1.1. NORTH AMERICA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.2. EUROPE TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.3. ASIA TOXOID VACCINES MARKET, BY COUNTRY 4.6.1.4. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET, BY COUNTRY CHAPTER 5: GLOBAL VACCINES MARKET, BY TYPE 5.1. OVERVIEW 5.2. MONOVALENT VACCINES 5.2.1. MONOVALENT VACCINES MARKET, BY REGION 5.2.1.1. NORTH AMERICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.2. EUROPE MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.3. ASIA MONOVALENT VACCINES MARKET, BY COUNTRY 5.2.1.4. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET, BY COUNTRY 5.3. MULTIVALENT VACCINES 5.3.1. MULTIVALENT VACCINES MARKET, BY REGION 5.3.1.1. NORTH AMERICA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.2. EUROPE MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.3. ASIA MULTIVALENT VACCINES MARKET, BY COUNTRY 5.3.1.4. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET, BY COUNTRY CHAPTER 6: GLOBAL VACCINES MARKET, BY ROUTE OF ADMINISTRATION 6.1. OVERVIEW 6.2. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION 6.2.1. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY REGION 6.2.1.1. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.2. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.3. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.2.1.4. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET, BY COUNTRY 6.3. ORAL ADMINISTRATION 6.3.1. ORAL ADMINISTRATION MARKET, BY REGION 6.3.1.1. NORTH AMERICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.2. EUROPE ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.3. ASIA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.3.1.4. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET, BY COUNTRY 6.4. OTHER ROUTES OF ADMINISTRATION 6.4.1. OTHER ROUTES OF ADMINISTRATION MARKET, BY REGION 6.4.1.1. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.2. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.3. ASIA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY 6.4.1.4. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET, BY COUNTRY TABLE 01. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 02. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 03. TABLE 04. SOURCE: PRIMARY RESEARCH, GOVERNMENT PUBLICATIONS, COMPANY RELEASES, AND 1000IQMR ANALYSISGLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 05. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 06. GLOBAL VACCINES MARKET VALUE, BY REGION, 2023-2030, ($MILLION) TABLE 07. EUROPE VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($MILLION) TABLE 08. EUROPE VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($MILLION) TABLE 09. EUROPE VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($MILLION) TABLE 10. EUROPE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 11. GERMANY VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 12. GERMANY VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 13. GERMANY VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 14. UK VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 15. UK VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 16. UK VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 17. FRANCE VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 18. FRANCE VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 19. FRANCE VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 20. ITALY VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 21. ITALY VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 22. ITALY VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 23. SPAIN VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 24. SPAIN VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 25. SPAIN VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 26. ROE VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 27. ROE VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 28. ROE VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 29. GLOBAL VACCINES MARKET VALUE, BY TECHNOLOGY, 2023-2030, ($ MILLION) TABLE 30. CONJUGATE VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 31. NORTH AMERICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 32. EUROPE CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 33. ASIA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 34. MIDDLE EAST & AFRICA CONJUGATE VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 35. INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 36. NORTH AMERICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 37. EUROPE INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 38. ASIA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 39. MIDDLE EAST & AFRICA INACTIVATED AND SUBUNIT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 40. LIVE ATTENUATED VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 41. NORTH AMERICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 42. EUROPE LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 43. ASIA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 44. MIDDLE EAST & AFRICA LIVE ATTENUATED VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 45. RECOMBINANT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 46. NORTH AMERICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 47. EUROPE RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 48. ASIA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 49. MIDDLE EAST & AFRICA RECOMBINANT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 50. TOXOID VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 51. NORTH AMERICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 52. EUROPE TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 53. ASIA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 54. MIDDLE EAST & AFRICA TOXOID VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 55. GLOBAL VACCINES MARKET VALUE, BY TYPE, 2023-2030, ($ MILLION) TABLE 56. MONOVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 57. NORTH AMERICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 58. EUROPE MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 59. ASIA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 60. MIDDLE EAST & AFRICA MONOVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 61. MULTIVALENT VACCINES MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 62. NORTH AMERICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 63. EUROPE MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 64. ASIA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 65. MIDDLE EAST & AFRICA MULTIVALENT VACCINES MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 66. GLOBAL VACCINES MARKET VALUE, BY ROUTE OF ADMINISTRATION, 2023-2030, ($ MILLION) TABLE 67. INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 68. NORTH AMERICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 69. EUROPE INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 70. ASIA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 71. MIDDLE EAST & AFRICA INTRAMUSCULAR AND SUBCUTANEOUS ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 72. ORAL ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 73. NORTH AMERICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 74. EUROPE ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 75. ASIA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 76. MIDDLE EAST & AFRICA ORAL ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 77. OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY REGION, 2023-2030, ($ MILLION) TABLE 78. NORTH AMERICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 79. EUROPE OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 80. ASIA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION) TABLE 81. MIDDLE EAST & AFRICA OTHER ROUTES OF ADMINISTRATION MARKET VALUE, BY COUNTRY, 2023-2030, ($MILLION)